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Background and objectives: Chronic kidney disease (CKD) and atherosclerosis are 2 interrelated
diseases that increase the risk of cardiovascular morbidity and mortality. The objectives
of  the ILERVAS project are: (1) to determine the prevalence of subclinical arterial disease
and hidden kidney disease; (2) to assess the impact of early diagnosis of both diseases on
cardiovascular morbidity and mortality and also on the progression of CKD; (3) to have aeywords:
ardiovascular disease
therosclerotic plaque
platform of data and biological samples.
Methods: Randomised intervention study. From 2015 to 2017, 19,800 people (9900 in the inter-
vention group and 9900 in the control group) aged between 45 and 70 years without previous
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history of cardiovascular disease and with at least one cardiovascular risk factor will be
randomly selected from the primary health care centres across the province of Lleida. A
team  of experts will travel around in a mobile unit to carry out the following baseline tests
on  the intervention group: Artery ultrasound, (carotid, femoral, transcranial and abdominal
aorta), ankle-brachial index, spirometry, determination of advanced glycation end products,
dried blood spot and urine spot tests. Additionally, blood and urine samples will be collected
and stored in the biobank to identify new biomarkers using omics studies. Participants will
be  followed up until 2025 for identiﬁcation of cardiovascular events, treatment changes and
changes in lifestyle.
Conclusions: The ILERVAS project will reveal the prevalence of subclinical vascular disease
and  hidden kidney disease, determine whether or not their early diagnosis brings health
beneﬁts and will also allow investigation of new risk factors.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Estudio  de  intervención  aleatorizado  para  evaluar  la  prevalencia  de
enfermedad  ateromatosa  y  renal  ocultas  y  su  impacto  en  la
morbimortalidad:  Proyecto  ILERVAS
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r  e  s  u  m  e  n
Antecedentes y objetivos: La enfermedad renal crónica (ERC) y la ateromatosis son 2 enfer-
medades interrelacionadas que aumentan el riesgo de morbimortalidad cardiovascular. Los
objetivos del proyecto ILERVAS son: 1) conocer la prevalencia de enfermedad ateromatosa
subclínica y de enfermedad renal oculta; 2) valorar el impacto de su diagnóstico precoz sobre
la  morbimortalidad cardiovascular y la progresión de la ERC; 3) disponer de una plataforma
de  datos y muestras biológicas.
Métodos: Estudio de intervención aleatorizado. Entre 2015 y 2017 se incluirá a 19.800 per-
sonas (9.900 en el grupo de intervención y 9.900 en el grupo control) entre 45 y 70 an˜os,
sin  antecedentes de enfermedad cardiovascular y que presenten al menos un factor de
riesgo cardiovascular, seleccionadas aleatoriamente de los centros de atención primaria
(AP)  de la provincia de Lérida. Un equipo técnico experto se desplazará con una unidad
móvil  para realizar las exploraciones basales al grupo de intervención: ecografía arte-
rial  (carótida, femoral, transcraneal y aorta abdominal), medición del índice tobillo-brazo,
espirometría, detección de los productos de glicación avanzada y analítica seca de sangre
y  orina. Adicionalmente, se recogerán muestras de sangre y orina que serán almacenadas
en  el biobanco para identiﬁcar nuevos biomarcadores con biología de sistemas. Los par-
ticipantes serán seguidos hasta 2025 para la identiﬁcación de eventos cardiovasculares,
cambios de tratamiento y modiﬁcación de estilos de vida.
Conclusiones: El proyecto ILERVAS permitirá conocer la prevalencia de enfermedad vascular
y  de enfermedad renal subclínicas, evaluar si su diagnóstico precoz tiene un beneﬁcio en la
salud e investigar factores de riesgo emergentes.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Cardiovascular (CV) diseases are the leading cause of
morbidity and mortality worldwide, with a major social,
healthcare-related and economic impact. In 2012, in the Euro-
pean Union, CV disease accounted for 40% of overall mortality
with a cost of D 196 billion, distributed as follows: 54% for
healthcare spending, 24% for lost productivity and 22% for
care of patients with CV disease.1 In the same year, in Spain,by-nc-nd/4.0/).
CV disease accounted for 30% of all recorded deaths and 15%
of all hospital admissions.2 In the Spanish province of Lleida,
in 2012, CV disease was the leading cause of death, with a
prevalence of 26% of ischaemic heart disease of and 27%.of
cerebrovascular events.3
Risk calculation tables (Framingham, Score, Regicor) based
on traditional CV risk factors such as age, sex, smoking habit,
blood pressure, total cholesterol and diabetes have been used
to detect the population susceptible of having a CV event.
However, these calculations do not take into account other
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actors that also have an impact. These factors include, but
re not limited to a history of early CV disease in ﬁrst-degree
elatives (men before age 55, women before age 65), genetic
actors and individual susceptibility, obesity, socioeconomic
evel, sleep apnoea, and chronic kidney disease (CKD). It has
een indicated that more  than 60% of CV events occur in indi-
iduals with a low to moderate calculated risk, and that 4 of
very 10 cases of miocardial infarction or sudden death occur
n people with no prior history of CV disease.4
Numerous population studies, based on large cohorts and
ong periods of follow-up, have demonstrated a clear asso-
iation between the presence of an atheromatous plaque in
he carotid arteries and the risk of having a coronary or cere-
rovascular event (1.8–4.1, respectively), and have concluded
hat a diagnosis of subclinical atheromatosis increases the
redictive value of traditional risk equations, which reclas-
ify individuals according to degrees of risk greater than those
alculated by these algorithms.5–9
Atheromatous disease is characterised by a chronic, proli-
erative and multifactorial inﬂammatory process that affects
he vascular bed such that atheromatous plaques form in
edium- to large-sized arteries walls (carotid, femoral, cere-
ral, coronary and renal).10 The clinical manifestations will
epend on both the area and the number of vascular regions
ffected, and on the volume and vulnerability of the athero-
atous plaque which, through various mechanisms, may
ndergo rupture, formation of a thrombus and subsequent
nset of a CV event (ischaemic cerebrovascular accident, acute
yocardial infarction or ischaemia of the lower limbs).11
rtery ultrasound is a non-invasive, reproducible, validated
echnique with high sensitivity and speciﬁcity allowing a reli-
ble, cost-effective diagnosis of subclinical atheromatosis to
e made. Indeed, there is a gradual trend towards its inclu-
ion in current clinical guidelines for the management of CV
isk.12,13
One of the diseases with high CV mortality and a ele-
ated prevalence of atheromatosis is CKD.14,15 CKD gradually
ncreases with age (22% in those over age 64 and 40% of those
ver age 80), type 2 diabetes and hypertension (35–40% in
iabetic or hypertensive patients).16 Patients with CKD are
Fig. 1 – Exterior design of the mo
Artery ultrasound 
Ankle brachial index
Arterial blood pressure
Biochemical parameters
Biomarkers
Proteomics
Lipidomics
Metabolomics
ig. 2 – Diagnostic tests in the mobile unit. a The diagnostic test 
dvanced glycation end product; SAF: skin autoﬂuorescence.(4):389–396 391
asymptomatic until the disease is advanced and in the major-
ity of cases, at the time of the diagnosis of CKD the patient
requires referral to a specialised physician for replacement
treatment either with dialysis or transplantation, with a high
associated healthcare cost. In Spain, it is estimated that 10%
of the adult population (20% in those over age 65) have hid-
den kidney disease (HKD) and that 40% will die of CV disease
before entering a dialysis programme.17
Therefore, due to the high morbidity and mortality of sub-
clinical atheromatous disease (SAD) and HKD it is justiﬁed
to propose an epidemiological study to determine its preva-
lence in the asymptomatic population with at least one CV
risk factor. There are no studies addressing the impact of early
diagnosis of SAD and HKD on CV morbidity and mortality, CKD
progression and clinical management in primary care level
(PC).
In the ILERVAS study we propose performing an overall
assessment of CV and renal risk with non-invasive diagnos-
tic tools. To do this, we  propose a collaborative study that
involves different research groups from the Instituto de Inves-
tigación Biomédica de Lleida (IRBLleida) that will provide
speciﬁc diagnostic methods from their specialty, and that will
be conducted sequentially during the journey made by indi-
viduals within the mobile unit (MU) (Figs. 1 and 2).
The general aims of the ILERVAS proposal are:
(1) To determine the prevalence of SAD and HKD  in the
asymptomatic general population with at least one CV risk
factor.
(2) To analyse the impact of the interventions performed in
the MU on CV morbidity and mortality and CKD progres-
sion during a 10-year follow-up period.
(3) To have a platform for data encompassing baseline data
(clinical, clinical-chemistry and biobank) and follow-up
data allowing the association between the different known
and emerging risk factors and SAD, HKD, CV morbidity
and mortality, and CKD progression to be analysed. These
factors include:
a. Biomarkers (proteomics, metabolomics, lipidomics and
genetic polymorphisms).
bile unit (bus and caravan).
Diet and exercise
Anthropometric data
AGEs (SAF)a
Spirometry
Sleepiness test
used to measure AGEs is skin autoﬂuorescence. AGE:
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b. Lung capacity and sleep abnormalities.
c. Advanced glycation end products (AGEs).
d. Diet and physical activity.
e. Traditional risk factors.
Methods
Study  design  and  population
A randomised interventional study with 2 arms that will
include 19,800 individuals with at least one CV risk factor,
registered in PC in the province of Lleida, between January
2015 and December 2017, who  will subsequently be followed
up until January 2025. The ILERVAS study protocol, informa-
tion about the population, location of the MU, informative
videos and materials about CV disease, contact information
and publications will be available on the following website:
www.elbusdelasalut.cat/.
Source  of  information  and  instruments  for  data  collection
Sociodemographic variables (age, sex and race), medical his-
tory of comorbidities and medical treatments will be collected
from the electronic PC medical history (e-CAP).
The other variables will be collected in the MU, which
will travel throughout the province of Lleida. This MU  is has
the equipment to perform vascular diagnostic tests, spirom-
etry and collection of anthropometric and clinical-chemistry
data. In addition, variables related to physical exercise will
be collected from the International Physical Activity Ques-
tionnaire (IPAQ),18 variables related to diet will be collected
from the diet survey adapted from the PREDIMED study19 and
variables related to daytime somnolence will be collected
Patients with an open medical record in the e-CAP
n=410 246
(October 2014)a
Women aged 50-70 and men aged 45-65 with any CVRF: 
first-degree family history of e
n=46 069
Pa
myocar
surge
20 patients who can be visited on working
days (mobile unit) for 3 years
n=9900
12 days
Lleida capital
n=240
7 days
Regional capitals
n=140
CAPs>864
the in
4 days
CAPs 577–720 patients who
meet the inclusion criteria
n=80
3 days
CAPs 433–576 patients
who meet the inclusion criteria
n=60
C
Patien
selected
Randomisation
Fig. 3 – Population selection diagram for the ILERVAS project. a R
centre; CV: cardiovascular; CKD: chronic kidney disease; CVRF: ca;3 6(4):389–396
from the Berlin questionnaire20 and the Epworth somnolence
scale.21
Each week, all ILERVAS study data entered in the e-CAP will
be extracted for quality control and to be exported to a general
database designed for this purpose.
Participant  selection
The participant selection process is shown in Fig. 3. From a
total of 410,246 people with an open history in the e-CAP
(on October 24, 2014), the study population that meets the
inclusion criteria will be identiﬁed. The inclusion criteria are:
women between the ages of 50 and 70 and men between the
ages of 45 and 65 with at least one CV risk factor (hyper-
tension, dyslipidaemia, obesity, smoking habit, ﬁrst-degree
family history of early CV disease), no prior medical history
of CV disease, diabetes, CKD or active neoplasm, and a life
expectancy no shorter than 18 months (n = 46,069). Of these,
a total of 19,800 people (9900 in the intervention group and
9900 in the control group) will be selected through simple ran-
domisation without replacement, within clusters deﬁned by
basic healthcare area, PC centre or doctor’s ofﬁce, in accor-
dance with the total number of people who may be visited in
the MU during f one year period (20 patients per working day).
Each day 10 people will be added to cover a potential non-
response rate of up to 50%. Finally, 3300 people per year will
be studied in the MU, following selection of a total of 4950 can-
didates each year. From the second year of the study, sample
selection will be performed every six months. People who  have
participated in previous years will be excluded. To identify the
population with no electronic medical history in the e-CAP (Val
d’Aran, Solsonès and Cerdanya) the ILERVAS team will request
information from the responsible of each healthcare area.
hypertension, dyslipidaemia, obesity, smoking,
arly CV disease
tients with a diagnosis of diabetes, CKD, CV disease (angina,
dial infarction, stroke, peripheral artery disease, history of vascular
ry), active neoplasm, life expectancy <18 months, institutionalised
population n=364 177
6 days
 patients who meet
clusion criteria
n=120
5 days
CAPs 721–864 patients who
meet the inclusion criteria
n=100
2 days
APs 289– 432 patients who
meet the inclusion criteria
n=40
1 day
CAPs<288 patients who
meet the inclusion criteria
n=20
ts who will not be visited by the mobile unit but will be randomly
 following the same protocol as the MU group for later comparison
n=9900
andomised by cluster (CAP) annually. CAP: primary care
rdiovascular risk factor; MU:  mobile unit.
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The participants selected will be informed of the study
bjectives and the diagnostic tests to be performed by means
f a personalised letter with an appointment day and time.
rior to the inclussion in the study they must sign the
nformed consent form. The study protocol has been approved
y the Hospital Universitario Arnau de Vilanova (Lleida) Ethics
ommittee.
One month before the MU  reaches each population, 2 inves-
igators responsible for the project will travel to hold meetings
n information and updates about subclinical atheromatous
rterial disease, HKD and abdominal aortic aneurysm; to
xplain the project to healthcare workers and administra-
ors of the different healthcare basic areas; and to help with
he interpretation of the results of the examinations and
ecommendations that will be included in the ILERVAS ﬁnal
eport in the electronic medical history of each patient which
re based on clinical practice guidelines10,22–25 (Appendix B:
upplementary material).
ollow-up  period
s this is an asymptomatic population with a low to mod-
rate CV risk, a minimum 10-year follow-up period has been
stablished to observe the onset of CV events.26,27 Initially the
ohort will be followed up from January 2015 to January 2025.
he follow-up period may be lengthened, given that all data
ill be recorded in the e-CAP. The population selected will
e monitored every six months to collect changes in medical
istory related to the study objectives.
ardiovascular  events  and  CKD  progression
he onset of a CV event will be recorded according to the
enth version of the International Statistical Classiﬁcation of
iseases (ICD-10), which includes: angina pectoris, myocar-
ial infarction, transient ischaemic attack, cerebrovascular
ccident, heart failure, arrhythmia, peripheral artery disease,
ortic aneurysm, revascularisation and angioplasty of any
rtery region. Likewise, the patient’s cause of death, whether
f CV origin (myocardial infarction, arrhythmia, heart failure,
erebrovascular accident, aortic aneurysm, mesenteric infarc-
ion or sudden death) or of non-CV origin (infections, cancers,
ccident or kidney disease) will be recorded.
The information sources used to identify CV events will be:
eview of medical records (through the e-CAP) and consulta-
ion of the Catalonia mortality registry.
CKD progression is deﬁned as a doubling of creatinine or
ntry into renal replacement therapy, and will also be collected
hrough the e-CAP.
ascular  ultrasound
he examination and reading will be performed by 2 nurses
pecialised in vascular imaging diagnostics, following a stan-
ardised protocol with the patient in supine decubitus.28 The
IVID I version BT12 ultrasound system (GE Healthcare) will be
sed. The system has a 12L-RS/4–13 MHz  linear probe (ultra-
ound of the carotid and femoral arteries), a 4C-RS/1.5–6 MHz
onvex probe (ultrasound of the abdominal aorta) and a 3S-
S/1.5–2.5 MHz  sector probe (transcranial ultrasound). It also(4):389–396 393
has a module for measuring intima-media thickness and
pulsed Doppler ultrasound to assess haemodynamic abnor-
malities in the case that atheromatous plaques are present,
and also to analyse the intracranial circulation. The DICOM
network connectivity system will be used to record the results
and ultrasound images online in the e-CAP.
Carotid  arteries
A total of 8 vascular regions will be analysed (common carotid,
bifurcation or bulb, internal carotid and external carotid),
with the patient in supine decubitus and the head turned 45◦
towards the opposite side in the examination. The transver-
sal examination will be started with a 2D longitudinal slice of
the common carotid up to the bifurcation. At this level colour
Doppler will be used to distinguish the external carotid from
the internal carotid and then examine both carotids simulta-
neously.
The presence of an atheromatous plaque will be identi-
ﬁed as an intima-media thickness with a height greater than
1.5 mm.28 In the event that a plaque is demonstrated, the
degree of stenosis (<50%, 50–70% or 70–99%) will be quantiﬁed
by colour and pulsed Doppler and the peak systolic veloc-
ity (PSV in cm/s), peak diastolic velocity (PDV cm/s) and ratio
(between common carotid and the location of the stenosis)
will be determined to assess the degree of haemodynamic
abnormality.
Femoral  arteries
With the patient in supine decubitus, the presence of a plaque
will be examined in the common femoral artery (1 cm proxi-
mal  to the bifurcation) and the superﬁcial femoral artery on
both sides. The same criterion will be followed for deﬁnition
of an atheromatous plaque.
Abdominal  aorta
The aim is to measure the diameter of the abdominal aorta
for early diagnosis of aortic aneurysm in men  age 60 and
older. With the patient in supine decubitus, the abdominal
aorta will be examined in the midline of the abdomen from
the base of the sternum until the bifurcation the iliac arteries
is visualised. In an axial view, at the points where a greater
diameter is observed, 2 images of the aorta will be captured,
and 2 measurements will be made (anterior–posterior and
lateral–lateral). An aortic aneurysm will be considered to be
present when the diameter is greater than 3 cm.
Transcranial  ultrasound
The arteries of the circle of Willis and their branches will
be insonated through the transtemporal and transforaminal
acoustic windows. The Doppler spectrum of each intracranial
artery will be determined using the colour-coded signal. Flow
direction, peak systolic velocity, mean ﬂow velocity and dia-
stolic ﬂow velocity will be established. The intracranial carotid
artery, the medial cerebral artery in the M1 and M2  segments,
the anterior cerebral artery (segment A1) and the posterior
cerebral artery in segments P1 and P2 will be studied through
the transtemporal acoustic window.
The V4 segment of the vertebral arteries and the basilar
artery will be studied through the transforaminal acoustic
window. In each patient the number, location and severity
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of stenoses will be recorded. Baumgartner’s criteria will be
used to establish the severity of the stenosis based on peak
systolic wave  velocity (moderate to serious stenosis, if it is
≥155/≥220 cm/s for the medial cerebral artery, ≤120/≥155 cm/s
for the anterior cerebral artery, ≥100/≥145 cm/s for the poste-
rior cerebral artery and the basilar artery, and ≥90/≥120 cm/s
for the vertebral artery).29
Ankle–brachial  index
A continuous Doppler (Hadecco ES100X MiniDop), sphygmo-
manometer and blood pressure cuffs (Riester minimus III)
will be used. Systolic blood pressure will be measured in the
brachial artery, posterior tibial artery and dorsalis pedis artery
in both limbs. The ratios between tibial and pedal systolic
blood pressure in each leg and the higher brachial blood pres-
sure will be calculated. The ﬁnal value for each limb will be
the lower value of those obtained between tibial and pedal
blood pressure.30 An ankle–brachial index value <0.9 will be
considered to be suggestive of stenosis; a value <0.7 will be
considered to be stenosis and a value ≥1.4 will be considered
to be suggestive of rigidity.
Spirometry
Spirometry will be used to assess lung capacity. It will be
performed by the same nurse who will measure forced vital
capacity (FVC); forced expiratory volume in one second (FEV1);
the ratio between FEV1 and FVC and the lower limit of normal-
ity, as a percentage.
Determination  of  advanced  glycation  end  products
These will be measured using skin autoﬂuorescence (SAF)
in the forearm with the AGE Reader® system (Diagnoptics,
the Netherlands). SAF is measured using spectrophotometry
which is calculated as the relationship of the intensity of
reﬂected light compared to refracted light. The result obtained
will be divided into 4 CV risk groups, taking into account age
and sex.
Clinical  and  clinical-chemistry  data
The following variables will be recorded:
- Weight, height, waist circumference and neck circumfer-
ence. Self-calculable body mass index in kg/m2.
- Systolic blood pressure, diastolic blood pressure and pulse
pressure (mmHg). These will be measured 3 times (Omron
6) at 2-min intervals and the mean of the last 2 will be col-
lected.
- Hours of fasting.
- Dried capillary blood testing (ﬁngertip puncture): creati-
nine (mg/dl), uric acid (mg/dl) and total cholesterol (mg/dl),
using the Reﬂotrons® Plus system (Roche). Determination
of the complete lipid proﬁle in cases in which total choles-
terol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL
cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101®
system [Roche]). Calculation of non-HDL cholesterol lev-
els (total cholesterol – HDL cholesterol [mg/dl]). Glycated;3 6(4):389–396
haemoglobin (%) will be analysed with the Cobas B 101 sys-
tem (Roche).
- From the creatinine value, taking into account race and sex,
the CKD-EPI glomerular ﬁltration rate will be determined.31
- Urine sample laboratory testing: using Clinitek Microal-
bumin 2 Reagent Strips and a Siemens Clinitek Status®
analyser from a urine sample from spontaneous micturition
collected in the bus itself (which has a bathroom): albumin-
uria (mg/l) and albumin/creatinine ratio (mg/g).
Biobank
- Drawing of blood samples from a peripheral vein of the
hand or forearm to obtain serum, plasma, DNA and RNA.
These samples will be prepared in aliquots following a stan-
dardised protocol, and sent frozen (dry ice) to a centralised
biobank (RedinRen at Universidad de Alcalá) for processing
and storage for subsequent studies of CV, inﬂammatory
and mineral-metabolism biomarkers and genetic polymor-
phisms.
- Urine samples frozen and stored in a biobank for subse-
quent study of biomarkers.
Statistical  analysis
Descriptive analysis will include absolute and relative fre-
quencies for the qualitative variables, means and standard
deviations for the continuous variables that follow a normal
distribution, and median and interquartile range in the cases
that do not follow a normal distribution. Their distribution
will be analysed with the chi-squared test, in the case of
qualitative variables, and Student’s t test or ANOVA for quan-
titative variables with a normal distribution, or, failing this,
non-parametric Mann–Whitney U or Kruskal–Wallis tests will
be used for those without a normal distribution. The corre-
lation between quantitative variables will be analysed using
Pearson’s or Spearman’s test, depending on the distribution.
Variables with outliers will be processed for their standard-
isation and subsequent analysis. The existence of collinearity
between 2 variables will be analysed to enter the variable that
better predicts the result variable in the multivariate model.
Multivariate analysis will be performed using logistic
regression if the dependent variable is qualitative, or linear
regression if it is quantitative. Beta regression coefﬁcients,
odds ratios (ORs) and their respective 95% conﬁdence intervals
will be estimated as measures of association. In the longi-
tudinal study, the incidence of CV morbidity and mortality
and mortality due to any cause will be analysed, based on
the diagnostic tests used in the MU and the biomarkers stud-
ied using Cox regression. Statistical signiﬁcance will be set
at a p value < 0.05. The SPSS version 21 (SPSS Inc. Chicago,
United States) software program will be used for data analysis.
The results will be weighted by the inverse of the prob-
ability of selection which requires the selection strategy
applied in the sampling phase. Results will be provided for
both the entire province and each predeﬁned territory within
the province, applying the corresponding post-stratiﬁcation
weights in each case.
An initial general data analysis in the ﬁrst 3 months of each
year (January–March 2016, 2017 and 2018) is planned.
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The ﬁrst publication will make reference to the over-
ll results of the study (prevalence of atheromatous disease
nd HKD). Subsequently potential differences in prevalence
etween regions and the effects of diet, exercise, changes in
abits, changes in medication and other factors will be ana-
ysed.
In a second phase, the relationship between CV events
major and minor) and CKD progression for the group that has
een included in the MU compared to the group with the same
nclusion criteria, but that has not been studied in the MU, will
e analysed.
iscussion
he ILERVAS project is the ﬁrst study that will make a diag-
osis of the prevalence of SAD and HKD in an asymptomatic
opulation with at least one CV risk factor and link both dis-
ases with CV morbidity and mortality over time (10 years). In
ddition, it will determine whether early diagnosis of both dis-
ases results in a health beneﬁt. It will also contribute to the
nowledge on the impact of respiratory diseases and biomark-
rs on CV risk and will show the prevalence of unknown cases
f diabetes, dyslipidaemia and hyperuricaemia. One notable
onsideration is that this will allow inequalities in health
inked to region, diet and socioeconomic level to be detected.
The use of imaging diagnostic tools will allow early
dentiﬁcation of atheromatous disease and therefore early
dentiﬁcation of patients with a high risk of having a CV event
n the future. In addition, this project has an added value in
erms of primary prevention. In this regard, healthcare edu-
ation that will emphasise modiﬁable risk factors common to
ll the diseases studied, such as obesity, smoking habit, seden-
ary lifestyle and hypertension, will be carried out in the MU
nd at the PC centres.
Working with a shared medical history will enrich the
roject, allow long-term follow-up of patients and reveal the
mpact of early diagnosis of atheromatosis (artery ultrasound)
n CV prediction, management and prevention, as well as HKD
etection, on the incidence of dialysis, compared to those
atients with the same risk factors who have not visited the
U and who are managed according to conventional CV risk
alculation population tables. In addition, assessment of new
iomarkers and genetic polymorphisms will add predictive
alue to the known risk factors for both diseases. Knowledge
f factors may set the basis for the development of a more
recise and personalised care that should help to reduce the
ncidence of these diseases.
An added value is that this database will be fed without
nterruption, as it will be shared with the electronic his-
ory used daily in PC, which will allow access to clinical
nd clinical-chemistry parameters and CV events throughout
ime. All this, together with the parameters of proteomics,
etabolomics, genetic polymorphisms and other biomarkers,
ill contribute to the creation of a large-scale database. Its
nalysis (computation and modelling) will involve the collabo-
ation of experts in management of big data from the Scientiﬁc
nd Technical Department at IRBLleida.
Moreover, it is not known what are the challenges that the
uture may bring us regarding potential biomarkers that could(4):389–396 395
allow the design of a medicine personalised with respect to
risk factors and treatments. Therefore, plasma, serum, RNA,
DNA and urine samples will be collected; these will be avail-
able for external investigators, after presentation of projects
that will be evaluated by a scientiﬁc committee, which will
take into account both the quality of the project and the assur-
ance of having the resources required to complete it.
In conclusion, the ILERVAS project aims to achieve a
paradigm shift in the diagnosis of CKD and vascular disease,
through improvement in accessibility of part of the popula-
tion with risk factors to cost-effective interventions that allow
early prevention of the onset and progression of these dis-
eases. This will result in a reduction in the socioeconomic
and health impact (reduction in hospitalisations and social
and healthcare costs); which in large part are associated to a
late diagnosis.
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